Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2025-04-18 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
中天国富证券有限公司关于美康生物科技股份有限公司2024年度募集资金存放与实际使用情况的专项核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from a securities company (中天国富证券有限公司) regarding the 2024 annual special audit opinion on the deposit and actual use of raised funds by 美康生物科技股份有限公司. It includes extensive information on the amount of funds raised, their usage over multiple years, management and storage of the funds, investment projects funded by the raised capital, changes in project timelines, and compliance with regulatory requirements. The document also contains audit opinions and verification from accounting firms and the sponsor institution. The content focuses on the management and use of capital raised through stock issuance, which aligns with the category of Capital/Financing Update (CAP). The document is not a general annual report, earnings release, or regulatory filing, but a specialized report on the use of raised funds, which fits the CAP category best.
2025-04-18 Chinese
2024年年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "审计报告及财务报表" which translates to "Audit Report and Financial Statements" for the fiscal year 2024 (January 1, 2024 to December 31, 2024). It contains detailed audit opinions, key audit matters, auditor responsibilities, and extensive financial statements including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements. The presence of an auditor's opinion, detailed audit procedures, and full financial statements indicates this is a standalone audit report rather than a full annual report or a simple announcement. The document length is substantial (15,000 characters), and it includes substantive financial data and analysis. Therefore, the document fits the category of an Audit Report / Information (AR). FY 2024
2025-04-18 Chinese
公司2025年度高级管理人员薪酬与考核方案
Remuneration Information Classification · 95% confidence The document is titled '2025 年度高级管理人员薪酬与考核方案' which translates to '2025 Annual Senior Management Compensation and Assessment Plan'. It details the principles, structure, and procedures for determining and assessing senior management compensation. It references the company's board of directors and the board's compensation and assessment committee, but it does not contain financial statements or results. The content focuses on remuneration policies and assessment mechanisms for senior management, which aligns with the definition of Remuneration Information filings. The document length is 1566 characters, which is relatively short but contains substantive policy details rather than just an announcement or summary. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2025-04-18 Chinese
2024年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the fiscal year ending December 31, 2024, issued by the company's board of directors. It discusses the evaluation of the company's internal control effectiveness, covering financial and non-financial controls, defect classifications, and compliance with regulatory standards. The content is focused on internal control assessment rather than full financial statements or audit opinions. It is not an annual report (10-K), audit report (AR), or interim report (IR), but rather a specialized internal control evaluation report. Given the nature of the document, it fits best under Audit Report / Information (AR), which includes applied accounting principles and internal control evaluations separate from full annual reports. FY 2024
2025-04-18 Chinese
关于作废2023年限制性股票激励计划首次授予部分已授予但尚未归属的第二类限制性股票的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from 美康生物科技股份有限公司 regarding the cancellation of a portion of restricted stock granted under the 2023 restricted stock incentive plan. It details board and supervisory committee meetings, approvals, legal opinions, and the impact of the cancellation on the company and shareholders. The content focuses on corporate governance and management decisions related to stock incentives, not on financial results or earnings. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting results announcement. The document is a formal announcement of a board decision concerning management and board matters, specifically about stock incentive plan adjustments. Therefore, it fits best under Board/Management Information (MANG). The document length is moderate and contains detailed information about board resolutions and management decisions, not just a brief notice or regulatory filing. Confidence is high due to clear focus on board decisions and stock incentive plan management.
2025-04-18 Chinese
2024年年度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (519 characters) from Meikang Biotechnology Co., Ltd. It states that the company's 2024 Annual Report and its summary have been approved and will be disclosed on April 19, 2025, on the designated information disclosure website. The text does not contain the actual annual report or financial data but rather informs investors about the upcoming publication of the full report. According to the 'MENU VS MEAL' rule, such a brief notice about the report's disclosure is classified as a Report Publication Announcement (RPA), not the Annual Report (10-K) itself.
2025-04-18 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.